The agreement gives EQT's more than 300 portfolio companies early access to 1X's commercial production capacity and integration expertise. Adoption decisions will be taken individually by each company, but the partnership sets the foundation for one of the world's first large-scale commercial rollouts of humanoid robots. The companies will focus on applications in logistics, industrial software, facility operations, warehousing, manufacturing, and healthcare. Pilots are set to launch in the United States in 2026, with rapid scaling across Europe and Asia to follow. 1X, backed by EQT Ventures, is the developer of NEO, promoted as the first ready-to-ship humanoid robot. Founder and CEO Bernt Oivind Bornich said: 'This partnership brings humanoid robotics into the real economy. EQT's global reach and operational expertise make them the ideal partner to help deploy our technology safely, responsibly, and at scale.' Ted Persson, lead partner at EQT Ventures, said humanoid robotics is now moving from fiction into deployment. 'This isn't about replacing people, it's about giving them superpowers,' he said. He added that offering the technology across EQT's portfolio could help companies address labour shortages, strengthen safety, and improve productivity....
The agreement reduces total net debt by about one-third to '1.2bn and injects '285m of new financing. The deal also extends the maturity of Colisee's senior facilities to 2031. Almost all financial creditors approved the plan, which follows months of negotiations triggered by a missed interest payment earlier this year. CVC Credit, KKR, Blackstone, and HIG Capital were among the lenders steering the restructuring. The creditor-led recapitalisation ends EQT's ownership of Colisee, which it acquired in 2020. EQT had tabled a competing proposal involving new equity and a partial write-off, but it failed to gain creditor support. Chief executive Arnaud Marion will continue in his role under the new ownership. Colisee, Europe's fourth-largest elderly care provider, expects to complete the restructuring by April 2026 through an accelerated safeguard proceeding in the French courts. The takeover highlights how private credit funds are increasingly dictating outcomes in stressed European healthcare deals, as rising rates and delayed asset sales push leveraged operators into complex recapitalisations....
The company plans to offer 179 million shares at $26 to $30 each. It has secured $2.35bn in cornerstone commitments from major global investors including Baillie Gifford, Capital Group, Janus Henderson, GIC, Viking Global Investors, Durable Capital Partners, and Morgan Stanley's Counterpoint Global. Members of the Mills family, Medline's founders, may acquire up to $250m of shares in the IPO. If priced at the top end, Medline's flotation would eclipse all US listings this year and represent one of the largest private equity realisations since the 2011 HCA Healthcare offering. It also surpasses the $1.75bn Venture Global IPO, currently the biggest US listing of 2025. Medline reported $977m in net income on $20.6bn in revenue for the nine months to September 27, up from $911m on $18.7bn a year earlier. The company expects tariff-related costs of $325m to $375m in fiscal 2025, and a further $150m to $200m in 2026. The Mills family founded Medline in 1966. The business was taken private again in 2021 when Blackstone, Carlyle, and Hellman & Friedman acquired it in a $34bn leveraged buyout, one of the largest in history. Since then, Medline has expanded through acquisitions, including Ecolab's surgical solutions unit for $905m in 2024, and invested $1.6bn into its distribution network....
Cassandra Willyard is a journalist who covers health and science with a focus on infectious disease, public health and drug development. Her work has appeared in the Atlantic, Nature and the New York Times. Detectives often find important clues by digging through rubbish. That approach paid off tremendously for systems biologist Yifat Merbl. When she and her team investigated cellular recycling centres known as proteasomes, they uncovered an entirely new part of the immune system. From her office at the Weizmann Institute of Science in Rehovot, Israel, she holds up a blue plastic model of a proteasome, a barrel-shaped structure with a hollow core. The function seems simple: proteins enter the chamber, where they are shredded and then exit as smaller peptide fragments. But the machinery is surprisingly elaborate. The core comprises more than two dozen protein subunits and can associate with a variety of regulatory caps. If the goal is to slice and dice proteins, Merbl wondered, why the need for such complexity'...
